BTK and respiratory failure: The addition of the BTK inhibitor acalabrutinib to best supportive care in patients with SARS-CoV-2 respiratory symptoms also failed to increase the proportion of patients who remained alive and free of respiratory failure in the two phase II CALAVI trials (NCT04380688 and NCT04346199); the formal publications of these two studies are awaited.